Raphael Brandão Moreira

960 total citations · 1 hit paper
30 papers, 719 citations indexed

About

Raphael Brandão Moreira is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Raphael Brandão Moreira has authored 30 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 13 papers in Cancer Research. Recurrent topics in Raphael Brandão Moreira's work include Renal cell carcinoma treatment (11 papers), Cancer Genomics and Diagnostics (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Raphael Brandão Moreira is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Cancer Genomics and Diagnostics (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Raphael Brandão Moreira collaborates with scholars based in United States, Brazil and Canada. Raphael Brandão Moreira's co-authors include Toni K. Choueiri, Guillermo de Velasco, Joaquim Bellmunt, Fabio A.B. Schutz, Dominick Bossé, F. Stephen Hodi, Mark M. Awad, Guru Sonpavde, Patrick A. Ott and Youjin Je and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Oncotarget.

In The Last Decade

Raphael Brandão Moreira

29 papers receiving 712 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

2017 369 citations Guillermo de Velasco, Youjin Je et al. Cancer Immunology Research profile →

Peers

Raphael Brandão Moreira

ONCOL

PRM

IMMUN

J.M. Sánchez-Torres Spain

Rebecca S. Tidwell United States

Jinhyun Cho South Korea

Mona Fouad Egypt

Amaury Daste France

Katherine A. Scilla United States

Yukihiro Toi Japan

Keita Kudo Japan

Delphine Topart France

Maria Bassanelli Italy

J.M. Sánchez-Torres Spain

Raphael Brandão Moreira

614 ×1.2

ONCOL

428 ×1.2

PRM

99 ×0.9

IMMUN

150 ×1.4

104 ×1.1

Citations per year, relative to Raphael Brandão Moreira Raphael Brandão Moreira (= 1×) peers J.M. Sánchez-Torres

Countries citing papers authored by Raphael Brandão Moreira

Since Specialization

Citations

This map shows the geographic impact of Raphael Brandão Moreira's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raphael Brandão Moreira with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raphael Brandão Moreira more than expected).

Fields of papers citing papers by Raphael Brandão Moreira

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raphael Brandão Moreira. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raphael Brandão Moreira. The network helps show where Raphael Brandão Moreira may publish in the future.

Co-authorship network of co-authors of Raphael Brandão Moreira

This figure shows the co-authorship network connecting the top 25 collaborators of Raphael Brandão Moreira. A scholar is included among the top collaborators of Raphael Brandão Moreira based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raphael Brandão Moreira. Raphael Brandão Moreira is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Moreira, Raphael Brandão, et al.. (2022). Body mass index and immune checkpoint inhibitor efficacy in metastatic cancer patients: A Brazilian retrospective study. 2. 3 indexed citations

Abrahão, Ana Beatriz Kinupe, et al.. (2021). Palliative Prognostic Index accuracy of survival prediction in an inpatient palliative care service at a Brazilian tertiary hospital. ecancermedicalscience. 15. 1228–1228. 6 indexed citations

Araújo, Raphael L. C., et al.. (2019). Disappearing colorectal liver metastases: Strategies for the management of patients achieving a radiographic complete response after systemic chemotherapy. Journal of Surgical Oncology. 121(5). 848–856. 10 indexed citations

Sun, Maxine, Guillermo de Velasco, Priscilla K. Brastianos, et al.. (2018). The Development of Brain Metastases in Patients with Renal Cell Carcinoma: Epidemiologic Trends, Survival, and Clinical Risk Factors Using a Population-based Cohort. European Urology Focus. 5(3). 474–481. 40 indexed citations

Hamieh, Lana, Raphael Brandão Moreira, Xun Lin, et al.. (2018). Impact of Aspirin and Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs on Outcomes in Patients with Metastatic Renal Cell Carcinoma. 2(1). 37–46. 2 indexed citations

Yip, Steven, J. Connor Wells, Raphael Brandão Moreira, et al.. (2018). Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer. 124(18). 3677–3683. 55 indexed citations

Velasco, Guillermo de, Youjin Je, Dominick Bossé, et al.. (2017). Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. Cancer Immunology Research. 5(4). 312–318. 369 indexed citations breakdown →

Moreira, Raphael Brandão, Lana Hamieh, Evisa Gjini, et al.. (2017). Regression of multifocoal in transit melanoma metastases after palliative resection of dominant masses and 2 years after treatment with ipilimumab. Journal for ImmunoTherapy of Cancer. 5(1). 61–61. 2 indexed citations

Harshman, Lauren C., Wanling Xie, Raphael Brandão Moreira, et al.. (2017). Evaluation of disease-free survival as an intermediate metric for overall survival in localized renal cell carcinoma: A trial-level meta-analysis.. Journal of Clinical Oncology. 35(15_suppl). 4585–4585. 1 indexed citations

10.

Moreira, Raphael Brandão, Márcio Debiasi, Edoardo Francini, et al.. (2017). Differential side effects profile in patients with mCRPC treated with abiraterone or enzalutamide: a meta-analysis of randomized controlled trials. Oncotarget. 8(48). 84572–84578. 69 indexed citations

11.

Miao, Diana, Guillermo de Velasco, Dennis O. Adeegbe, et al.. (2017). Abstract A18: Genomic and neoantigen evolution and resistance to immune checkpoint blockade in metastatic renal cell carcinoma. Cancer Immunology Research. 5(3_Supplement). A18–A18. 1 indexed citations

12.

Moreira, Raphael Brandão, Rana R. McKay, Wanling Xie, et al.. (2017). Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).. Journal of Clinical Oncology. 35(6_suppl). 482–482. 10 indexed citations

13.

Pignon, Jean‐Christophe, Opeyemi A. Jegede, Kathleen M. Mahoney, et al.. (2017). Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8⁺ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology. 35(6_suppl). 477–477. 9 indexed citations

14.

Hamieh, Lana, Rana R. McKay, Xun Lin, et al.. (2016). Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 15(2). 221–229. 21 indexed citations

15.

Fay, André P., et al.. (2016). The management of immune-related adverse events associated with immune checkpoint blockade. 1(1). 89–97. 13 indexed citations

16.

Moreira, Raphael Brandão, Márcio Debiasi, Fernando Cotait Maluf, et al.. (2016). Differential side effects profile in mCRPC patients treated with abiraterone or enzalutamide: A meta-analysis of randomized controlled trials.. Journal of Clinical Oncology. 34(2_suppl). 73–73. 5 indexed citations

17.

Moreira, Raphael Brandão, et al.. (2015). Clinical Response to Sorafenib in a Patient with Metastatic Colorectal Cancer and FLT3 Amplification. Case Reports in Oncology. 8(1). 83–87. 19 indexed citations

18.

Moreira, Raphael Brandão, et al.. (2015). Next-generation sequencing (NGS) in metastatic breast cancer (mBC) patients: Translation from sequence data into clinical practice.. Journal of Clinical Oncology. 33(28_suppl). 133–133. 4 indexed citations

19.

Moreira, Raphael Brandão, et al.. (2015). Role of second-line gemcitabine after FOLFIRINOX failure in advanced pancreatic adenocarcinoma: A retrospective analysis.. Journal of Clinical Oncology. 33(3_suppl). 473–473. 1 indexed citations

20.

Buzaid, Antônio C., et al.. (2013). Low-Dose Bevacizumab Is Effective in Radiation-Induced Necrosis. Case Reports in Oncology. 6(3). 598–601. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact